A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma.

Trial Profile

A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Tosedostat (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2007 The phase II portion of this trial in now fully recruited and results are expected in the first half of 2008.
    • 13 Dec 2007 Status changed from initiated to in progress.
    • 30 Nov 2007 Chroma will present efficacy data from this trial at the 49th Annual Meeting and Exposition of the American Society of Hematology, held from 8-11 December in Atlanta, Georgia, USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top